Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224)

British Journal of Cancer

Volumn 98, Issue 4, 2008, Pages 776-783

  Donate F ^a   Juarez, J C ^a   Burnett, M E ^a   Manuia, M M ^a   Guan, X ^a   Shaw, D E ^b   Smith, E L P ^c   Timucin, C ^c   Braunstein, M J ^c   Batuman, O A ^c   Mazar, A P ^a  

^a Attenuon LLC   (United States)

^b D E SHAW RESEARCH   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Biomarkers; Circulating progenitor cells; Superoxide dismutase; Tetrathiomolybdate

Indexed keywords

ATN 224; CERULOPLASMIN; CHOLINE TETRATHIOMOLYBDIC ACID; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; MATRIGEL; TETRATHIOMOLYBDIC ACID; UNCLASSIFIED DRUG;

ADOLESCENT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; MACACA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOLOGICAL MARKERS; BLOOD CELLS; COLLAGEN; COPPER; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; LAMININ; MACACA RADIATA; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLYBDENUM; PROTEOGLYCANS; STEM CELLS; SUPEROXIDE DISMUTASE;

EID: 39449103259     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604226     Document Type: Article

References (26)

1. Berenson JR, Boccia RV, Bashey A, Levine AM, Koc ON, Callahan JA, Mazar AP, Reich SD (2006) Phase I study of the [Cu, Zn] superoxide dismutase (SOD1) inhibitor ATN-224 (Bis-choline tetrathiomolybdate) in patients (pts) with advanced hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 108. Abstracts 2593
2. Bertolini F, Shaked Y, Mancuso P, Kerbel RS (2006) The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6: 835-845
3. Bhatt RS, Seth P, Sukhatme VP (2007) Biomarkers for monitoring antiangiogenic therapy. Clin Cancer Res 15: 777s-780s
4. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD (2000) Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res 6: 1-10
5. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438: 932-936
6. Doñate F (2005) Anti-angiogenic therapy in cancer. Drugs Future 30: 695-707
7. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438: 967-974
8. Goodman VL, Brewer GJ, Merajver SD (2005) Control of copper status for cancer therapy. Curr Cancer Drug Targets 5: 543-549
9. Hassouneh B, Islam M, Nagel T, Pan Q, Merajver SD, Teknos TN (2007) Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther 6: 1039-1045
10. Johnson WT, Johnson LA, Lukaski HC (2005) Serum superoxide dismutase 3 (extracellular superoxide dismutase) activity is a sensitive indicator of Cu status in rats. J Nutr Biochem 11: 682-692
11. Juarez JC, Betancourt Jr O, Pirie-Shepherd SR, Guan X, Price ML, Shaw DE, Mazar AP, Doñate F (2006) Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res 12: 4974-4982
12. Juarez JC, Guan X, Shipulina NV, Plunkett ML, Parry GC, Shaw DE, Zhang JC, Rabbani SA, McCrae KR, Mazar AP, Morgan WT, Doñate F (2002) Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Cancer Res 62: 5344- 5350
13. Lowndes SA, Adams A, Timms A, Middleton M, Hayward C, Reich SD, Mazar AP, Harris AL (2006) Phase I study of ATN-224 in patients (pts) with advanced solid tumours. 2006 ASCO Annual Meeting Proceedings Part I 24, No. 18S
14. Lowndes SA, Harris AL (2004) Copper chelation as an antiangiogenic therapy. Oncol Res 14: 529-539
15. Meyer LA, Durley AP, Prohaska JR, Harris ZL (2001) Copper transport and metabolism are normal in aceruloplasminemic mice. J Biol Chem 276: 36857-36861
16. Milne DB (1998) Copper intake and assessment of copper status. Am J Clin Nutr 67(Suppl 5): 1041S-1045S
17. Nozik-Grayck E, Suliman HB, Piantadosi CA (2005) Extracellular superoxide dismutase. Int J Biochem Cell Biol 12: 2466-2471
18. Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD (2003a) Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther 2: 617-622
19. Pan Q, Bao LW, Merajver SD (2003b) Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkB signaling cascade. Mol Cancer Res 1: 701-706
20. Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD, Brewer GJ, Merajver SD (2002) Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62: 4854-4859
21. Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD (2003) Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9: 1666-1672
22. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, Kerbel RS (2005) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 1: 101-111
23. Tasaki H, Yamashita K, Tsutsui M, Kamezaki F, Kubara T, Tanaka S, Sasaguri Y, Adachi T, Nakashima Y (2006) Heparin-released extracellular superoxide dismutase is reduced in patients with coronary artery atherosclerosis. Atherosclerosis 187: 131-138
24. Uauy R, Castillo-Duran C, Fisberg M, Fernandez N, Valenzuela A (1985) Red cell superoxide dismutase activity as an index of human copper nutrition. J Nutr 115: 1650-1655
25. Vassiliev V, Harris ZL, Zatta P (2005) Ceruloplasmin in neurodegenerative diseases. Brain Res Brain Res Rev 49: 633-640
26. Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L, Dai K, Berenson JR, Hussain MM, Klueppelberg U, Norin AJ, Akman HO, Ozçelik T, Batuman OA (2005) Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 105: 3286-3294